Lorita

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorita

What is Lorita? Identity and Purpose

Lorita is the trade name for a medication whose active ingredient is Loratadine, a widely used compound for managing symptoms associated with allergic conditions. Loratadine is a synthetic, long-acting agent that provides systemic anti-allergic relief, fundamentally defined by its ability to modulate the body's response to allergens.

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Oral solution
Pharmacological class H1-receptor Antagonist
Common use Symptomatic relief of allergies
Origin Synthetic, Piperidine derivative

What Type of Medicine is Lorita? (Classification & Definition)

Lorita contains the active substance Loratadine, which is classified as a second-generation antihistamine. This chemical entity belongs to the pharmacological class of H1-receptor antagonists, meaning it works by selectively preventing the chemical substance histamine from binding to its receptors in the body's peripheral tissues. Loratadine's established therapeutic utility is recognized by its inclusion on the List of Essential Medicines.


How Does Lorita Relieve Allergic Symptoms? (General Purpose & Unique Feature)

The general purpose of Lorita is to provide symptomatic relief by counteracting the effects of histamine, a natural chemical released during an immune response to allergens. By acting as an anti-allergic agent, the drug helps mitigate the typical discomforts of an allergic reaction, which is clinically recognized for providing twenty-four-hour efficacy. Loratadine's profile results in significantly less sedation than older drugs, even at therapeutic doses. This indicates that the drug allows patients to manage allergy symptoms without significant impairment to cognitive function or alertness.


Loratadine Forms and Chemical Origin (Composition & Presentation)

The medication is a single-active-ingredient product derived from a Piperidine derivative chemical structure. For oral administration, Loratadine is available in several common pharmaceutical preparations, including the standard tablet, the liquid syrup or oral solution, and the specialized orally disintegrating tablet (ODT). The syrup form is often positioned for the pediatric patient group, offering an easier method of intake than tablets. Loratadine is effective over a twenty-four-hour period due to its long-acting profile. This feature allows the patient to maintain continuous symptom control with once-daily intake.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
  2. MedlinePlus Drug Information on Loratadine
  3. Loratadine - StatPearls - NCBI Bookshelf

What side effects are possible with Lorita?

Possible Side Effects and Safety Information

The adverse reaction profile for Lorita (Loratadine) is formally documented in regulatory texts and organized by frequency and System-Organ Class (SOC) categories. The profile identifies specific effects reported during clinical use and post-marketing surveillance.


Frequency-Classified Adverse Reactions

The most frequent effects reported in clinical trials for adults and adolescents include Somnolence (drowsiness) and Headache, which are considered common adverse reactions. In children aged 2 through 12 years, the most commonly reported reactions in excess of placebo were Headache, Nervousness, and Fatigue.

Reactions classified as Uncommon include Insomnia and Increased appetite.

A broad range of reactions are classified as Very Rare (incidence less than 1 in 10,000), covering multiple organ systems.


Systemic Safety and Serious Reactions

The officially listed adverse reactions involve several system-organ classes, including Nervous system disorders (e.g., dizziness, somnolence) and Gastrointestinal disorders (e.g., dry mouth, nausea, gastritis).

Very Rare and clinically significant adverse reactions cited in regulatory documents include Hypersensitivity reactions (such as anaphylaxis and angioedema), Convulsion, Tachycardia (fast heartbeat), Palpitation, and Abnormal hepatic function.


Population-Specific Safety Notes

Official labeling addresses specific populations where clearance may be altered. For patients with Severe Hepatic Impairment (severe liver disease), a lower initial dose may be required. Furthermore, the use of the medicine should be discontinued at least 48 hours before conducting skin tests to avoid interference with the results of the dermal reactivity index. The label also notes that taking more than the directed dose may cause drowsiness.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official overdose information for Loratadine (Lorita) based strictly on governmental regulatory documents, focusing solely on documented manifestations and mandated emergency actions.


Overdose Scope

Feature Regulatory Statement
Documented overdose presentations: The manifestations reported are somnolence, tachycardia, and headache. Overdosage increases the occurrence of anticholinergic symptoms.
Physiological systems affected: Central Nervous System, Cardiovascular System, and Autonomic Nervous System are documented systems affected.
Dose-related factors: Somnolence has been observed in studies at doses two to four times higher than the usual recommended daily dose.
Emergency-response statements: Get medical help right away and Contact a Poison Control Center right away.
When immediate help is required: Seek immediate medical attention following any suspected overdosage.

Overdose Management & Constraints

Classification Aspect Official Regulatory Statement
Severity classification: The requirement to seek immediate medical attention and documented tachycardia indicate potential for serious effects.
Antidote Status: No specific antidote is known. The substance is not removed by haemodialysis.

Official Overdose Statements

  • Overdosage is associated with documented clinical manifestations, including somnolence, headache, and tachycardia.
  • The mandated action is to seek immediate medical attention and/or contact a Poison Control Center right away.
  • Treatment is specified as being symptomatic and supportive, and procedures such as the use of activated charcoal or gastric lavage may be considered.
  • Medical monitoring of the patient is to be continued following the initiation of emergency management.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile through the observation of dose-related clinical signs, primarily affecting the nervous and cardiovascular systems, such as somnolence and tachycardia. These manifestations explicitly mandate the requirement to seek immediate medical attention, establishing the regulatory condition for when urgent help must be sought. Furthermore, the profile dictates a non-specific management strategy relying on symptomatic and supportive measures, acknowledging that no specific antidote is known.

Therapeutic Uses of Lorita

What Lorita Treats: Main Uses and Benefits

Lorita is generally used in conditions characterized by periods of heightened symptoms associated with acute or recurrent episodes of allergic discomfort. The medication is considered relevant for easing symptom clusters that may become intense or disruptive, such as frequent sneezing, runny nose, nasal itching, and irritative watery eyes. It is commonly applied in scenarios where short-term symptomatic assistance is needed for conditions like seasonal and perennial allergic rhinitis and Chronic Idiopathic Urticaria.


The medication may be part of symptomatic management for certain allergic skin conditions, including hives. Its application may assist with managing pruritus (itching) and the appearance of recurring wheals or hives, which provides support that helps ease the overall symptom burden.

“The use supports the patient during difficult episodes by easing distress and may contribute to maintaining functional stability.”

Quick Fact: Relief for Allergic Discomfort Lorita generally supports the patient by offering symptomatic relief over a 24-hour period. This long-acting profile may contribute to improved day-to-day comfort, which assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lorita — Official Regulatory Information

The eligibility for using Lorita (Loratadine) is defined by official regulatory bodies based on age, physiological status, organ function, and known allergies.

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults, adolescents (12 years), and children 2 to 11 years of age.
Populations for whom use is not recommended (if applicable): Breastfeeding mothers; children under 2 years of age.
Populations for whom use is contraindicated: Patients with documented hypersensitivity to Loratadine or any component of the formulation.

Age and Condition-Specific Eligibility Rules

  • Age-related eligibility rules: Safety and efficacy have not been established in children under 2 years of age, and use is therefore not recommended in this group. While older adults generally do not require dose adjustment, the evaluation of renal function is advised.
  • Condition-specific eligibility rules: Patients with severe hepatic impairment (liver disease) or severe renal impairment (GFR <30 mL/min) require conditional use, typically involving a reduced initial dose administered every other day.
  • Pregnancy and lactation eligibility status: Use during lactation is not recommended because Loratadine is excreted into breast milk. Use during pregnancy is advised only when the potential benefit is deemed to outweigh the potential risk.
  • Eligibility-related restrictions: Lorita use must be discontinued at least 48 hours before administering skin allergy tests to prevent interference with test results.

Connection to the overall eligibility profile

Official regulatory documents establish who can and cannot use the medicine by first defining absolute contraindications (hypersensitivity to ingredients). They then define restricted eligibility for specific physiological states, requiring conditional use for populations with severe hepatic or renal impairment. Finally, eligibility is formally structured by age and reproductive status, with use established for children 2 years and older but explicitly not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Lorita (loratadine) is structured around the potential for pharmacokinetic drug interactions where concurrent medicinal products may impair its clearance from the body, leading to increased plasma concentrations.


Documented Pharmacokinetic Interactions

The primary mechanism of interaction involves the inhibition of liver enzymes Cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP2D6, which are responsible for the metabolism of Lorita. The following specific medicines have been explicitly listed in regulatory labeling due to this effect:

Interacting Product Category Specific Interacting Medicines Listed
Enzyme Inhibitors Ketoconazole, Erythromycin, Cimetidine

Concurrent use with these inhibitors has been associated with substantially increased plasma concentrations of Lorita and its active metabolite, descarboethoxyloratadine. While controlled studies have generally not shown corresponding increases in the incidence of adverse effects with these specific agents, the drug-drug interaction is deemed clinically significant due to the potential for elevated drug levels.


Population-Specific Constraints

The official labeling notes that patients with pre-existing hepatic impairment (liver disease) or renal impairment (kidney disease), and the elderly, are at greater risk of experiencing somnolence when taking Lorita, as these conditions naturally impair the drug's clearance. This population-specific note highlights a constraint for use where reduced clearance—from either disease or a drug interaction—may increase the potential for effects like somnolence.

Mechanism of Action

Selective Blocking of Peripheral Histamine H1 Receptors

This mechanism is defined by the drug's role as a competitive antagonist that binds directly to peripheral H1 receptors, preventing the binding of the natural mediator, histamine. This action suppresses the initial molecular signal that initiates signaling cascades characteristic of immediate hypersensitivity. By modulating the histamine signaling pathway, the mechanism restricts histamine-induced stimulation of nerve endings and maintains microvascular integrity.

Non-Penetration of the Blood-Brain Barrier (BBB)

Lorita’s action is highly selective for peripheral targets because its chemical structure limits its ability to cross the Blood-Brain Barrier (BBB). This physiological restriction ensures that the drug has minimal interaction with central H1 receptors, which are key regulators of wakefulness. This mechanism results in minimal occupation of central H1 receptors.

Regulation of Vascular Permeability and Smooth Muscle Tone

The H1 receptor antagonism directly influences vascular endothelial function and smooth muscle cell activity. By preventing histamine's action on blood vessel walls, the mechanism affects capillary permeability and decreases fluid extravasation into tissues. Simultaneously, the blockade mitigates histamine-mediated contraction of smooth muscles in the airways and gastrointestinal tract, resulting in modulation of smooth muscle contractility.

Dosage and Administration Information

How Lorita is Used: Official Administration Guidelines

Lorita (loratadine) is administered according to a standard, once-daily schedule that is consistent across its approved dosage forms, which include the 10 mg tablet, oral solution, and the orally disintegrating tablet (ODT). The route of administration for all forms is strictly oral.


Labeled Dosing Schedule

Age Group / Condition Standard Labeled Regimen Maximum Daily Dose
Adults and Children 6 years or older 10 mg once daily 10 mg
Children 2 to 5 years 5 mg once daily 5 mg
Severe Hepatic or Renal Impairment 10 mg every other day (for patients >30 kg) 10 mg (over 48 hours)

The official maximum dose across all age groups and formulations is 10 mg in any 24-hour period. No dosage adjustment is generally required for older adults.


Administration and Procedural Rules

Lorita is taken once daily and may be administered with or without food. The frequency pattern is based on the drug's established 24-hour duration of action.

Procedural Instruction Detail
Dose Timing Take the dose without regard to mealtime. ODTs should be placed on the tongue to dissolve.
Missed Dose If a dose is missed, take it when remembered; however, skip the missed dose if it is almost time for the next scheduled dose. Do not take a double dose.
Special Constraint Administration must be discontinued for at least 48 hours prior to any diagnostic allergy skin testing to prevent interference with test results.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Loratadine (Lorita)

This overview summarizes the official research evidence for Loratadine, focusing on the types of studies conducted, the outcomes they measured, and what remains uncertain, based on official regulatory and scientific literature. The information provided is descriptive and does not constitute clinical advice.


Evidence for Symptom Relief in Seasonal Allergic Rhinitis (SAR)

Research exploring short-term symptom changes in seasonal allergic rhinitis relies heavily on randomized controlled trials (RCTs). Studies were applied in research contexts involving fluctuating or unstable symptoms, comparing Loratadine against a placebo or other active allergy medications. Studies monitored outcomes related to physical discomfort by tracking detailed symptom scores, such as sneezing, runny nose, nasal itching, and irritative, watery eyes. Research examined these symptom scores during the study period. Studies explored the time needed for the measured effect to begin (onset of action) and how long the measured effect appeared to last (duration), and research describes patterns observed over periods up to 24 hours. Evidence for effects on the specific symptom of nasal congestion is noted as a research area where data may be less consistent. Furthermore, evidence remains limited regarding the long-term outcomes for patients who require continuous treatment across multiple allergy seasons, as most pivotal studies focused on short, defined intervals.

Evidence for Managing Chronic Hives (Chronic Idiopathic Urticaria)

Loratadine was studied for its use in conditions involving periods of heightened symptoms, specifically Chronic Idiopathic Urticaria (CIU), also known as chronic spontaneous urticaria (hives). Studies monitored patient-reported outcomes describing perceived discomfort by using the Urticaria Activity Score (UAS). This score tracked outcomes related to systemic or functional imbalance by measuring the intensity of pruritus (itching) and the number/size of wheals (hives). Clinical trials monitored the overall UAS over the study duration. A key research limitation is that the results apply only to the populations studied—specifically, those with idiopathic (unknown cause) hives.

What Research Shows Is Still Uncertain

Research describes what is currently known and what remains uncertain regarding Loratadine's clinical evaluation. Although research has explored numerous outcomes, there is limited information for long-term outcomes, especially regarding the sustained use of the drug over many years. Follow-up durations were limited in the most definitive randomized trials, meaning the data available primarily reflects short-term outcomes. Evidence is limited and heterogeneous regarding its use in certain special populations, such as older adults or during pregnancy.

Key Studies & References

  1. Loratadine - StatPearls (used for general evidence context and indication confirmation)
  2. WHO Model List of Essential Medicines - Loratadine (used to confirm regulatory status and global relevance)

Frequently Asked Questions (FAQ)

Common questions about Lorita (FAQ)

Q: How quickly does Lorita typically start working?

Studies and official information indicate that the antihistaminic effect of Lorita can begin within approximately one to three hours after taking a dose. The measured effect typically reaches its maximum benefit between eight and twelve hours after administration.

Q: How long does the effect of one dose of Lorita last?

Clinical studies examining the medication’s effect on physical symptoms describe an effect that lasts in excess of 24 hours. This long duration of action is the basis for the medicine’s regulatory-approved, once-daily dosing regimen.

Q: Can Lorita be taken with cold and flu medicines?

Regulatory documents list specific prescription medicines that interact with Lorita by affecting how your body processes it. For over-the-counter cold and flu preparations, individuals are advised to check the ingredients on the cold and flu medicine label, especially for those that may also cause drowsiness, as combining them could potentially increase that effect.

Q: What happens if Lorita is taken with alcohol?

While official regulatory documents do not state a direct chemical interaction with alcohol, consuming it may increase the potential for certain side effects. Because Lorita may cause some drowsiness or dizziness in some people, combining it with alcohol may increase the potential for effects such as impaired coordination.

Q: What should I watch out for in the first week of taking Lorita?

The most frequent effects reported in clinical trials, particularly when first starting the medication, include headache, somnolence (drowsiness), and fatigue. These effects are classified as common, meaning they were observed more often than in people taking a placebo.

Q: Is it true that Lorita is sometimes used for conditions not listed in the main uses?

Lorita has received regulatory approval for the relief of symptoms associated with Seasonal Allergic Rhinitis (SAR) and the management of symptoms of Chronic Hives (Chronic Idiopathic Urticaria). The clinical evidence summarized in official documents only supports these two approved uses.

Q: Does Lorita interact with common herbal supplements like St. John's Wort?

Official information primarily focuses on interactions with specific medicines that affect the body's drug-processing enzymes (known as CYP450 enzymes). Some medical information documents mention products like St. John's Wort for their potential to also affect these drug-metabolizing enzymes, indicating that review of the ingredients for potential interaction is appropriate.

Q: What kind of drug class does Lorita belong to?

Lorita (loratadine) is officially classified as a second-generation antihistamine. It is also sometimes referred to by its mechanism of action as a non-sedating H1 receptor antagonist.

Q: Is Lorita the same kind of medicine as [similar sounding drug]?

Lorita belongs to the second generation of antihistamines. The descriptive difference from older, first-generation antihistamines is its selectivity for H1 receptors outside of the brain and minimal ability to cross the blood-brain barrier.

Q: What makes Lorita different from other drugs for the same use?

The official product information highlights that Lorita's action is highly selective for H1 receptors in the body outside of the central nervous system. This selective peripheral action is described as minimizing interaction with central receptors, which helps minimize the potential for sedative effects at recommended doses.

Q: Do the side effects of Lorita usually go away after a while?

Side effects like drowsiness and headache are often noted to be more noticeable when a person first begins taking the medication. Regulatory sources classify these effects but do not provide guarantees on their duration, though they note the overall low incidence of side effects.

Q: Is Lorita safe for older adults to use?

Regulatory documents note that dosage adjustment is generally not required for older adults. However, it also notes that this population may be at greater risk for effects such as somnolence because the natural clearance of the drug from the body may be reduced.

Q: What is the general guidance on using Lorita during pregnancy?

Official guidance states that the medicine should be used during pregnancy only if the potential benefit to the mother is considered to outweigh any potential risk to the fetus. Data from multiple studies have generally been reassuring and have not suggested an increased risk of major fetal malformations.

Q: Can children or teenagers take Lorita?

Official dosing guidelines are established for children as young as two years old (at a specific dose), and for adults and children six years and older (at a higher dose). Use in children younger than two years is not addressed in standard regulatory labeling.

Q: Are there any age limits described in the official documents for Lorita use?

The lowest age for which an approved dosing schedule is provided in official documents is two years old. This age is the lower limit of the pediatric population described in the drug's label.

Q: Is Lorita habit-forming or addictive?

Lorita (loratadine) is not classified as a controlled substance by regulatory bodies in the United States and is not described in official documents as having potential for abuse or addiction.

Q: Can Lorita affect driving or operating machinery?

Official information advises that caution is warranted, and individuals are noted to wait until they know how the medicine affects them personally before driving or operating machinery. This is due to the reported risk of drowsiness or dizziness.

Q: Is a specific warning about liver function mentioned for Lorita?

Official labeling indicates that patients with pre-existing severe hepatic impairment (severe liver disease) may require a lower initial dose due to reduced clearance. Abnormal hepatic function has also been cited as a very rare adverse reaction reported during post-marketing surveillance.

Q: What happens if I take too much Lorita?

Taking more than the directed dose may cause symptoms such as increased drowsiness, fast heartbeat (tachycardia), and headache. Regulatory safety studies have indicated that severe cardiovascular events are not typically linked to overdoses of this generation of antihistamines.

Q: Does the efficacy of Lorita decrease over time?

Research summaries note that while the drug has been shown to be well-tolerated, evidence remains limited regarding continuous treatment over many years. Official documents do not contain definitive statements about the drug's efficacy decreasing over time or developing tolerance.

Q: Are there any known severe drug interactions with Lorita?

Official documents explicitly list interactions with enzyme inhibitors such as Ketoconazole, Erythromycin, and Cimetidine. The clinical significance is that these may lead to substantially elevated plasma concentrations of Lorita, potentially increasing the risk of adverse effects.

Q: Does Lorita affect birth control pills?

Regulatory documents listing specific drug interactions for Lorita do not include birth control medications (oral contraceptives) as one of the medicines known to cause a pharmacokinetic interaction.

Q: Can Lorita be crushed, split, or chewed?

Official administration guidelines describe the standard tablet as being swallowed whole, while the orally disintegrating tablet (ODT) is placed on the tongue to dissolve. No official instruction is provided in the administration section for altering the form of the standard tablet by crushing or splitting.

Q: Is there official information about using Lorita while breastfeeding?

Lorita and its active metabolite are excreted into human milk. While official guidance may advise caution, some authoritative sources consider it a preferred choice among antihistamines during breastfeeding due to the low amounts excreted into milk.

Q: How does Lorita compare to older treatments for the same condition?

Lorita is classified as a second-generation treatment. It is distinguished from older, first-generation antihistamines by its selective action on peripheral H1 receptors and reduced ability to cross the blood-brain barrier, which is described as minimizing the potential for sedation.

Q: Is it normal to have mild headaches when starting Lorita?

Headache is listed in the official safety profile as a common adverse reaction in both adults and children. This means it is among the effects reported frequently in clinical trials.

Q: Does Lorita have any warnings regarding sun exposure?

Official regulatory documents do not list specific warnings or precautions regarding sun exposure, sun sensitivity, or photosensitivity for Lorita in the sections dedicated to warnings or adverse reactions.

Q: How long does it take for Lorita to be completely out of my system?

The mean elimination half-life for Lorita's major active metabolite is approximately 28 hours. Based on this pharmacokinetic data, it would take several days of non-use for the drug to be substantially cleared from the body.

How should Lorita be stored and disposed of?

Storage Conditions

Lorita must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from excess heat and excessive moisture, and must be kept from freezing. All formulations must be stored in the original container, tightly closed, and kept out of the sight and reach of children.

Packaging and Stability

Do not use the medication if the seal is broken or if a blister unit is torn. For disposal of unused or expired product, the official regulatory guidance recommends using a drug take-back location or mail-back envelope. If those options are unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed in a container before being discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorita found in:

A-Z Index: